Lilly is still worth over $500 billion, but its market capitalisation has shed almost a third in the past year. With ...

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

Eli Lilly said will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, amid a White House push to ...

Novo Nordisk ’s oral weight loss drug, which has been submitted for approval in the US, helped trial participants lose about ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Lilly has been a long-time backer of Superluminal, with the US big pharma company taking part in a $120m Series A round in ...

Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down ...

Results involving the highest dose of orforglipron disappointed investors — but still bring the drug a step closer to ...

Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Eli Lilly’s new weight-loss daily pill underperformed against competitors in weight... The Competition and Consumer ...